Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting.

@article{Taussig2003DurableRO,
  title={Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting.},
  author={David Christopher Taussig and A. J. Davies and Jamie D. Cavenagh and Heather E Oakervee and Denise Syndercombe-Court and Stephen Kelsey and J. A. L. Amess and Ama Z. S. Rohatiner and T. Andrew Lister and Matt J. Barnett},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2003},
  volume={21 16},
  pages={3060-5}
}
PURPOSE To evaluate the use of reduced-intensity (RI) conditioning with allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical family donors in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). PATIENTS AND METHODS Sixteen patients (median age, 54 years; range, 37 to 66 years) underwent RI-HSCT using a conditioning regimen of fludarabine 25 mg/m2 daily for 5 days and either cyclophosphamide 1 g/m2 daily for 2 days (14 patients) or melphalan… CONTINUE READING
29 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Similar Papers

Loading similar papers…